Ticker: DXCM

Dexcom

Healthcare Healthcare Medical - Devices

Price 84.14

Reco Buy Potential 67 Risk 48 Updated 2026-09-10

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Dexcom, Inc. specializes in continuous glucose monitoring systems for diabetes management. Its core products include glucose sensors, transmitters, and software applications that provide real-time glucose data to users. The company primarily operates in the healthcare sector, with major revenue sources stemming from the sale of its monitoring devices and related services. Dexcom's technology aims to improve diabetes care and patient outcomes through innovative solutions.

Investment Profile

The investment profile of Dexcom is more aligned with growth investors, given its focus on innovation and market expansion in diabetes management. The absence of dividends and the current revenue trends suggest a focus on reinvestment for future growth rather than immediate returns. The stock may appeal to those with a medium to long-term investment horizon, looking for potential capital appreciation.

Category: Healthcare Sector: Healthcare Industry: Medical - Devices Investment style: Growth Horizon: Medium-term Company type: Market Leader

Fundamental metrics (experimental) Updated: 2026-09-07

EPS (TTM) — earnings per share for the last 12 months, $: 2.59
Revenue QoQ — quarter-over-quarter revenue growth: 9.8%
EPS surprise: 14.6%
20d volatility: 1.1%

AI recommendation changes

Date	Before	After	Reason
2026-09-08	Hold	Buy	Strong growth but recent momentum shows signs of weakness.
2026-09-06	Buy	Hold	Strong fundamentals but negative short-term momentum.
2026-08-08	Hold	Buy	Strong momentum, but revenue decline raises concerns.
2026-08-06	Buy	Hold	Weak fundamentals and high risk limit upside potential.
2026-08-01	Hold	Buy	Strong momentum and positive EPS surprise support growth outlook.
2026-07-09	Sell	Hold	Mixed performance; cautious outlook on revenue decline.
2026-07-01	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-06-21	Buy	Hold	Weak revenue growth and high risk factors present challenges.
2026-06-13	Hold	Buy	Strong momentum but recent revenue decline raises concerns.
2026-06-11	Buy	Hold	Weak revenue growth raises concerns despite positive EPS surprise.
2026-06-09	Hold	Buy	Strong momentum and positive EPS surprise support growth outlook.
2026-05-08	—	Hold	Weak fundamentals and negative momentum raise concerns.
2026-05-05	Sell	Hold	Компания показывает снижение выручки и негативную динамику на коротких временных интервалах, что указывает на определенные риски. Однако долгосрочные показатели остаются положительными, что позволяет рассматривать удержа
2026-04-27	Hold	Sell	Компания демонстрирует снижение цен на акции в краткосрочной перспективе, однако рост выручки и положительный сюрприз по EPS могут указывать на потенциальное восстановление. Рекомендуется удерживать акции до более ясных
2026-04-09	Sell	Hold	Компания показывает умеренный рост выручки и положительные сюрпризы по прибыли, но недавние колебания цен и отрицательная динамика за 20 и 60 дней вызывают осторожность.
2026-03-27	Hold	Sell	Компания Dexcom демонстрирует снижение цен акций в последние месяцы, что указывает на возможные проблемы с ростом. Однако стабильный рост выручки и положительное значение EPS могут свидетельствовать о долгосрочных перспе
2026-03-03	Buy	Hold	Компания показывает стабильный рост выручки и положительные результаты по EPS, однако недавнее снижение на 120 дней вызывает опасения. Рекомендуется удерживать акции до прояснения ситуации.
2026-02-22	Hold	Buy	Компания показывает сильный рост за последние 60 дней и положительную динамику выручки. Несмотря на небольшие колебания в краткосрочной перспективе, долгосрочные показатели выглядят многообещающе.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-08-04	Argus Research	Target Raised	86 → 96	86.9975
2026-08-03	Canaccord Genuity	Target Raised	82 → 90	83.45
2026-08-03	RBC Capital	Target Raised	— → 90	83.45
2026-07-31	Raymond James	Target Raised	91 → 94	82.66
2026-07-31	Piper Sandler	Target Raised	88 → 95	74.54
2026-07-31	Robert W. Baird	Target Raised	80 → 105	74.54
2026-07-31	BTIG	Target Raised	— → 90	74.54
2026-07-31	Truist Financial	Target Raised	— → 93	74.54
2026-07-31	Stifel Nicolaus	Target Raised	— → 95	74.54
2026-07-28	UBS	Update	— → 96	73.37
2026-07-16	Truist Financial	Target Raised	80 → 87	77.61
2026-06-23	Deutsche Bank	Update	— → 86	69.07
2026-06-15	Piper Sandler	Target Raised	75 → 88	75.37
2026-06-10	UBS	Target Raised	— → 95	78.415
2026-06-09	Mizuho Securities	Target Raised	— → 85	76.62
2026-06-08	Raymond James	Target Raised	81 → 91	76.62
2026-06-05	Stifel Nicolaus	Target Raised	85 → 90	72.59
2026-05-18	Canaccord Genuity	Target Lowered	100 → 82	61.63
2026-05-18	Barclays	Target Lowered	67 → 64	61.63
2026-05-01	Bernstein	Target Lowered	83 → 77	61.0308
2026-05-01	Robert W. Baird	Target Lowered	87 → 80	61.825
2026-05-01	Mizuho Securities	Target Lowered	90 → 75	61.65
2026-05-01	Raymond James	Target Lowered	83 → 81	59.55
2026-05-01	Canaccord Genuity	Target Raised	95 → 100	59.55
2026-05-01	Barclays	Target Lowered	72 → 67	59.55
2026-02-13	Robert W. Baird	Target Raised	82 → 87	70.67
2026-02-13	Mizuho Securities	Target Raised	78 → 90	65.08

News Page 1 of 1

Signos Secures $20 Million Funding to Expand AI-Driven Weight Loss Solutions in Partnership with Dexcom

05/27/2026, 06:34 AM economy fundraising healthcare Dexcom

Signos has secured $20 million in funding to enhance its AI-driven glucose monitoring system, which aims to capitalize on the growing demand for weight loss solutions linked to GLP-1 medications. This partnership with Dexcom could significantly increase its market presence as obesity rates rise in the U.S.